DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP POWDER FOR SOLUTION

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

DOXORUBICIN HYDROCHLORIDE

Доступна с:

PANDA PHARMACEUTICALS INC.

код АТС:

L01DB01

ИНН (Международная Имя):

DOXORUBICIN

дозировка:

50MG

Фармацевтическая форма:

POWDER FOR SOLUTION

состав:

DOXORUBICIN HYDROCHLORIDE 50MG

Администрация маршрут:

INTRAVENOUS

Штук в упаковке:

100

Тип рецепта:

Prescription

Терапевтические области:

ANTINEOPLASTIC AGENTS

Обзор продуктов:

Active ingredient group (AIG) number: 0110825003; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2017-08-16

Характеристики продукта

_Doxorubicin Hydrochloride for Injection USP _
_ _
_ _
_ _
_Page 1_
_ of 43_
_ _
PRODUCT MONOGRAPH
PR DOXORUBICIN HYDROCHLORIDE FOR INJECTION USP 50 MG / VIAL
Sterile Powder for Solution - Intravenous
THERAPEUTIC CLASSIFICATION
Antineoplastic Agent
PANDA PHARMACEUTICALS INC.
35 Nixon Road Unit 10
Caledon, ON
L7E 1K1
Control # 195868
Date of Preparation: August 11, 2017
_Doxorubicin Hydrochloride for Injection USP _
_ _
_ _
_ _
_Page 2_
_ of 43_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...............................................................................................
10
DRUG INTERACTIONS
................................................................................................
11
DOSAGE AND ADMINISTRATION
..............................................................................
12
OVERDOSAGE
............................................................................................................
16
STORAGE AND STABILITY
.........................................................................................
16
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................... 18
PART II: SCIENTIFIC INFORMATION
...........................................................................
18
PHARMACEUTICAL INFORMATION
...........................................................................
18
CLINICAL TRIALS
.........................